Open Access Open Access  Restricted Access Subscription or Fee Access

Reported side effects, bother, satisfaction, and adherence in patients taking hydrocodone for non-cancer pain

Kathryn P Anastassopoulos, MS, Wing Chow, PharmD, Crisanta I. Tapia, MHS, Rebecca Baik, BS, Bruce Moskowitz, MD, Myoung S. Kim, PhD


Objective: Pain is a prevalent condition that often involves a neuropathic component. Hydrocodone is one of the most widely used opioids for pain but is often associated with side effects (SEs). This study sought to characterize the experience of patients taking hydrocodone for non-cancer pain.
Methods: A nationwide survey of adults in the United States taking hydrocodone for non-cancer pain was conducted. The survey included questions to characterize these patients and their experience with hydrocodone-related SEs. A neuropathic pain subgroup also was examined.
Results: Among 630 respondents, the average age was 50.1 years (14.25). Most (90.6 percent) were Caucasian and 72.5 percent were female. Back pain or low back pain was the most common (42.1 percent) type of pain. Almost three-fourths (73.3 percent) experienced at least one SE, and 67.3 percent reported being bothered. More than three-fourths (78.3 percent) reported being satisfied with hydrocodone relieving pain; however, less (74.8 percent) reported being satisfied with it overall. More than one-fourth (27.6 percent) reported taking hydrocodone less than instructed with 41.4 percent of them reporting that SEs were bothersome as a reason. A greater percent of the neuropathic pain subgroup (266 respondents) experienced at least one SE (80.8 percent) and were bothered by them (75.6 percent). Overall satisfaction was slightly lower (71.1 percent) among these respondents, and among the 24.8 percent taking less than instructed, more than half (54.5 percent) reported that SEs were bothersome as a reason.
Conclusions: This study demonstrates an unmet need for better therapeutic options to manage pain, including neuropathic pain. Therapies that offer improved tolerability also may increase adherence, which could affect overall satisfaction and response to pain management.
Keywords: hydrocodone, opioids, side effects, bother, quality of life, pain relief, patient satisfaction, adherence

Full Text:



National Center for Health Statistics Health: special feature

on death and dying. Hyattsville, MD. 2011. Available at Accessed June 9, 2011.

Freynhagen R, Baron R: The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep. 2009; 13: 185-190.

Berger A, Dukes EM, Oster G: Clinical characteristics and economic costs of patients with painful neuropathic disorders.

J Pain. 2004; 5(3): 143-149.

McCarberg, BH, Nicholson BD, Todd KH, et al.: The impact

of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an internet survey. Am J Ther. 2008; 15(4): 312-320.

Bell T, Annuziata K, Leslie J: Opioid-induced constipation

negatively impacts pain management, productivity, and healthrelated quality of life: findings from the National Health and Wellness Survey. J Opioid Manag. 2009; 5(3): 137-144.

Kelly JP, Cook SF, Kaufman DW, et al.: Prevalence and characteristics of opioid use in the US adult population. Pain. 2008; 138: 507-513.

Swegle JM, Logemann C: Management of common opioidinduced adverse effects. Ann Fam Physician. 2006; 74(8): 1347-1354.

Benyamin R, Trescot AM, Datta S, et al.: Opioid complications and side effects. Pain Physician. 2008; 11: S105-S120.

Clinical Study Report Protocol R331333-PAI-3004

(KF5503/34): Randomized, double-blind, active-controlled, parallel- group, multiple-dose trial conducted in subjects with

chronic pain from low back pain or osteoarthritis of the hip or

knee of 3 months duration. Document ID No.: EDMS-PSDB-

:2; J&JPRD, 8 November 2007.

Ware JE Jr, Kosinski M, Turner-Bowker DM, et al.: User’s

Manual for the SF-12v2® Health Survey (with a Supplement

Documenting Version 1). Lincoln, RI: QualityMetric

Incorporated, 2002.

Cleeland CS: The Brief Pain Inventory User Guide.

Houston, TX: University of Texas MD Anderson Cancer Center, 2009.

Lerner D, Amick BC III, Rogers WH, et al.: The Work

Limitations Questionnaire. Med Care 2001; 39(1): 72-85.

Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006; 22(10): 1911-1920.

Bouhassira D, Attal N, Fermanian J, et al.: Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004; 108(3): 248-257.

Crawford B, Bouhassira D, Wong A, et al.: Conceptual adequacy of the neuropathic pain symptom inventory in six countries. Health Qual Life Outcomes. 2008; 18(6): 62.

Bouhassira D: Scaling and Scoring of the Neuropathic Pain

Symptom Inventory (NPSI), Version 1. Lyon, France: Mapi

Research Trust, 2008.

Pfizer Global Pharmaceuticals: painDETECT–Scoring of

Pain Questionnaire. Pfizer Global Pharmaceuticals, 2006.

Lerner D, Rogers W, Chang H: Technical Report: Scoring the Short Form of the Work Limitations Questionnaire (WLQ-SF). Tufts Medical Center. January 23, 2009.

Ware JE Jr, Kosinski M, Bjorner JB, et al.: User’s Manual

for the SF-36v2(tm) Health Survey, 2nd ed. Lincoln, RI:

QualityMetric, 2007.

Anastassopoulos K, Chow W, Ackerman S, et al.:

Oxycodone-related side effects: impact on degree of bother,

adherence, pain relief, satisfaction, and quality of life. J Opioid

Manag. 2011; 7(3): 203-215.

U.S. Census Bureau: Home computers and internet use in

the United States—table 2, October 2007. Available at Accessed October 17, 2011.

Chronic low back pain: novel therapies that offer improved

efficacy compared with current NSAIDs and opioids must also

have advantages in safety and tolerability. Decision Resources, LLC, March 2009. Available at Products-and-Services/Report?r=dbaspd3509. Accessed October 17, 2011.



  • There are currently no refbacks.